BUSINESS● LOWOct 5 · Oct 5, 2026, 6:17 AM
CSL strikes $1.55B lixudebart deal with Alentis for rare kidney and liver diseases
Seeking Alpha Tech · global
CSL has finalized a $1.55 billion deal with Alentis for the development of lixudebart, a treatment for rare kidney and liver diseases. This significant transaction impacts the pharmaceutical and biotechnology industries.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS22m agoIndia bars sugar-based ethanol in 2026-27 tender, cuts maize incentiveThe HinduBUSINESS27m agoFood Pantry Patrons Face ‘Too Much Month at the End of Their Money’NYT US